Document is current

Article History

Received: 9 January 2024

Accepted: 14 April 2024

First Online: 11 May 2024

Declarations

:

: The project was approved by the animal welfare committee of Bern (BE 111/18) and performed in accordance with the Swiss Ordinance on the Protection of Animals (TSchV 2008 455.1).

: Not applicable.

: The Department of Intensive Care Medicine has, or has had in the past, research contracts with Abionic SA, AVA AG, CSEM SA, Cube Dx GmbH, Cyto Sorbents Europe GmbH, Edwards Lifesciences LLC, GE Healthcare, ImaCor Inc., MedImmune LLC, Orion Corporation, and Phagenesis Ltd. and research and development/consulting contracts with Edwards Lifesciences LLC, Nestec SA, and Wyss Zurich. The money was paid into a departmental fund; no author received any personal financial gain. The Department of Intensive Care Medicine received unrestricted educational grants from the following organizations for organizing a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care (until 2015): Abbott AG, Anandic Medical Systems, Astellas, AstraZeneca, Bard Medica SA, Baxter, B | Braun, CSL Behring, Covidien, Fresenius Kabi, GSK, Lilly, Maquet, MSD, Novartis, Nycomed, Orion Pharma, Pfizer, and Pierre Fabre Pharma AG (formerly known as RobaPharm). The Department of Intensive Care Medicine has received unrestricted educational grants from the following organizations for organizing biannual postgraduate courses in the fields of critical care ultrasound, management of extracorporeal membrane oxygenation, and mechanical ventilation: Abbott AG, Anandic Medical Systems, Bard Medica SA., Bracco, Dräger Schweiz AG, Edwards Lifesciences AG, Fresenius Kabi (Schweiz) AG, Getinge Group Maquet AG, Hamilton Medical AG, Pierre Fabre Pharma AG (formerly known as RobaPharm), PanGas AG Healthcare, Pfizer AG, Orion Pharma, and Teleflex Medical GmbH.